NanoString announces publication of GeoMx DSP data
NanoString announced the publication of a study in the journal Nature Medicine that demonstrates the capability of the GeoMx digital spatial profiler, or DSP, to characterize toxicities associated with immunotherapy using checkpoint inhibitors. While checkpoint inhibitors can lead to durable responses in a range of metastatic cancers, unanticipated immune-related adverse events can limit the utility of these life-saving therapies. A group of researchers recently published a study entitled "A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor induced encephalitis." In this case report, investigators used the GeoMx DSP to characterize immune infiltrates in the brain of a patient who passed away from neurotoxicity following immunotherapy treatment for metastatic melanoma. The GeoMx DSP revealed the presence of activated T cells in the inflamed, non tumor-containing region of the brain. These T cells were characterized on other platforms and found to be potentially specific for Epstein Barr Virus-associated proteins. GeoMx DSP profiling of non-inflamed regions from the same patient, as well as patients with other forms of encephalitis, did not show evidence of activated T cells, suggesting that population was specific to the inflamed region within the immunotherapy treated patient.